Kit for detecting expression level of human ERCC1 (excision repair cross complementation 1) through PCR (polymerase chain reaction) method

Abstract

The invention provides a kit for detecting the expression level of ERCC1 (excision repair cross complementation 1). By adopting a fluorescent quantitative PCR (polymerase chain reaction) platform, and taking RNA (ribonucleic acid) reserved by culture cells as external calibration RNA and GapDH (reduced glyceraldehydes-phosphate dehydrogenase) as data of internal contrast gene normalization processing experiments, relative quantitative detection is carried out on the level of mRNA (messenger ribose nucleic acid) of ERCC1 of a sample tissue through a TaqMan probe method. The kit can be used for detecting the expression quantity of the ERCC1 at a level of mRNA and can reflect the gene expression level more truly; the detection data of the fluorescent quantitative PCR method is output by a machine, thus avoiding subjective identification of people and being more objective; the cultured cells are taken as the external RNA calibrator, and the whole process and the fluorescent quantitative PCR experiment are synchronous, so that the errors caused by the experiment process is reduced, the determination of the clinical cut-off value is realized, furthermore, the fluorescent quantitative PCR method for detecting the level of mRNA of ERCC1 is realized to be used in clinic.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

AI Technical Summary

Benefits of technology

This technology allows for precise measurement of certain genes that are involved in diseases such as breast cancer through analysis on patient samples collected from different locations around them over several months's period. It involves performing multiple reactions at once within an enclosed chamber called a tube where there is no air gap during this procedure. By measuring changes made throughout these steps, we aimed towards identifying potential causes like tumor growth or metastasis.

Problems solved by technology

This patents discuss various technical problem addressed during investigations into identifying potential therapic targets associated with EGFR activation and metabolism in lung carcinoma. Current methods involve measuring escalating lymph node biopsy data from patient samples followed upward through multiple steps before finding active agents targetable against these targets. These techniques may lead to imprecise diagnosis because they rely heavily on correlativity among other variables like histone variants and transcriptional activity. Therefore, novel assays capable of more accurate identification of possible therapeutic candidates would improve our understanding of how well responding treatments work towards lung cancer.

Images